BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma

NCT02872259 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

74

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

DRUG: BGB324+pembrolizumab
DRUG: BGB324+dabrafenib and trametinib
DRUG: pembrolizumab
DRUG: dabrafenib and trametinib

Sponsor

Haukeland University Hospital

Collaborators

[object Object]